Reply to the Correspondence regarding “Sequencing the anti-EGFR-TKIs; route to the longest survival” by H.G. Güzel et al.

We are grateful for the interest of H.G. Güzel et al.1 in our publication reporting the real-world outcomes of treatment strategy between first-line osimertinib, first-/second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) followed by osimertinib and without osimertinib in advanced EGFR-mutant non-small-cell lung cancer.2 We would like to take this opportunity to respond to some of the concerns raised by Güzel et al.